Dr. Sajatovic, Ms. Cassidy, and Dr. Blixen are with the Department of Psychiatry, Dr. Tatsuoka is with the Department of Neurology, and Dr. Gunzler, Dr. McCormick, Dr. Perzynski, Dr. Einstadter, Dr. Thomas, Dr. Seeholzer, and Dr. Dawson are with the Center for Health Care Research and Policy, all at Case Western Reserve University School of Medicine, Cleveland. Dr. Gunzler, Dr. McCormick, Dr. Perzynski, Dr. Einstadter, Dr. Thomas, and Dr. Dawson are also with MetroHealth Medical Center, Cleveland, where Ms. Kanuch, Ms. Lawless, and Ms. Martin are affiliated. Dr. Falck-Ytter is with the Louis Stokes Cleveland Veterans Affairs (VA) Medical Center, Cleveland. Dr. McKibben is with the Department of Psychology, University of Wyoming, Laramie. Dr. Bauer is with the Center for Healthcare Organization and Implementation Research, VA Boston Healthcare System, Jamaica Plain, Massachusetts, and with the Department of Psychiatry, Harvard Medical School, Boston.
Psychiatr Serv. 2017 Sep 1;68(9):883-890. doi: 10.1176/appi.ps.201600377. Epub 2017 May 15.
A 60-week randomized controlled trial assessed the effects of targeted training in illness management (TTIM) versus treatment as usual among 200 individuals with serious mental illness and diabetes mellitus.
The study used the Clinical Global Impression (CGI), the Montgomery-Asberg Depression Rating Scale (MADRS), and the Brief Psychiatric Rating Scale (BPRS) to assess psychiatric symptoms; the Global Assessment of Functioning (GAF) and the Sheehan Disability Scale (SDS) to assess functioning; the 36-Item Short-Form Health Survey (SF-36) to assess general health, and serum glycosylated hemoglobin (HbA1c) to assess diabetes control.
Participants' mean±SD age was 52.7±9.5 years, and 54% were African American. They were diagnosed as having depression (48%), schizophrenia (25%), and bipolar disorder (28%). At baseline, depression severity was substantial but psychosis severity was modest. At 60 weeks, there was greater improvement among TTIM participants versus treatment-as-usual recipients on the CGI (p<.001), the MADRS (p=.016), and the GAF (p=.003). Diabetes knowledge was significantly improved among TTIM participants but not in the treatment-as-usual group. In post hoc analyses among participants whose HbA1c levels at baseline met recommendations set by the American Diabetes Association for persons with high comorbidity (53%), TTIM participants had minimal change in HbA1c over the 60-week follow-up, whereas HbA1c levels worsened in the treatment-as-usual group.
TTIM was associated with improved psychiatric symptoms, functioning, and diabetes knowledge compared with treatment as usual. Among participants with better diabetes control at baseline, TTIM participants had better diabetes control at 60 weeks compared with recipients of treatment as usual.
一项为期 60 周的随机对照试验评估了针对患有严重精神疾病和糖尿病的 200 名个体的疾病管理目标培训(TTIM)与常规治疗的效果。
该研究使用临床总体印象(CGI)、蒙哥马利-阿斯伯格抑郁评定量表(MADRS)和简明精神病评定量表(BPRS)评估精神症状;使用总体功能评估(GAF)和 Sheehan 残疾量表(SDS)评估功能;使用 36 项简短健康调查(SF-36)评估一般健康状况,以及血清糖化血红蛋白(HbA1c)评估糖尿病控制情况。
参与者的平均年龄±标准差为 52.7±9.5 岁,54%为非裔美国人。他们被诊断患有抑郁症(48%)、精神分裂症(25%)和双相情感障碍(28%)。在基线时,抑郁严重程度较高,但精神病严重程度较轻。在 60 周时,与常规治疗组相比,TTIM 组在 CGI(p<.001)、MADRS(p=.016)和 GAF(p=.003)上的改善更大。糖尿病知识在 TTIM 组中显著提高,但在常规治疗组中没有提高。在基线时 HbA1c 水平符合美国糖尿病协会针对高合并症人群(53%)建议的参与者的事后分析中,与常规治疗组相比,TTIM 组在 60 周的随访中 HbA1c 水平几乎没有变化,而 HbA1c 水平在常规治疗组中恶化。
与常规治疗相比,TTIM 与改善精神症状、功能和糖尿病知识相关。在基线时糖尿病控制较好的参与者中,与常规治疗组相比,TTIM 组在 60 周时糖尿病控制更好。